Webinars
Feb 22, 2017
1:00 PM–2:00 PM (EST)
Online
Webinar
Duration: 1hrs
Pancreatic cancer is one of the most lethal malignancies with a poor prognosis. Understanding the mechanisms of tumor progression is therefore essential. Liquid biopsies are non-invasive methods for diagnostics to detect early stage cancer resulting in more successful treatment.  One liquid biopsy technique is the detection of RNA from tumor- derived exosomes. These exosomes participate in generating a metastatic niche. Using QIAGEN Bioinformatics solutions with a publicly available dataset, we have examined the transcriptome of Kupffer cells after uptake of pancreatic tumor-derived exosomes that induce the formation of a liver metastatic niche and analyzed the pathways and biological processes involved in this process.
Feb 23, 2017
Vienna, Austria

University of Vienna, Lecture Room 1
Währingerstraße 29, Vienna, Austria

Conference
Feb 23, 2017
1:00 PM–2:00 PM (EST)
Online
Webinar
Duration: 1hrs

Breast cancer is the most common cancer in women, accounting for 23% of all cancer diagnoses. Early detection of breast cancer metastasis would allow for changes in treatment strategy before the disease progression becomes apparent. In this webinar, we will demonstrate the enrichment and detection value – as well as the prognostic and predictive value – of the AdnaTestBreast in breast cancer.

 

Using the Combination of Combinations Principle (COCP), AdnaTest BreastCancer enables highly specific immunomagnetic cell selection for enriching circulating tumor cells (CTCs) from peripheral blood. It also allows sensitive analysis of breast cancer-associated gene expression in enriched CTCs by reverse transcription and PCR. The high performance of AdnaTest BreastCancer has been demonstrated in dozens of peer-reviewed publications. Several studies have reported that HER2 expression is different in primary tumors compared to CTCs. In addition, AdnaTestBreast HER2 overexpression profile corresponds to HER2 metastatic phenotype; and HER2 detected by the AdnaTestBreast and AdnaTest EMT-2/StemCell seems to initiate EMT and tumor stemness.

Feb 27, 2017
9:30 AM–10:30 AM (EST)
Online
Webinar
Duration: 1hrs

Breast cancer is the most common cancer in women, accounting for 23% of all cancer diagnoses. Early detection of breast cancer metastasis would allow for changes in treatment strategy before the disease progression becomes apparent. In this webinar, we will demonstrate the enrichment and detection value – as well as the prognostic and predictive value – of the AdnaTestBreast in breast cancer.

 

Using the Combination of Combinations Principle (COCP), AdnaTest BreastCancer enables highly specific immunomagnetic cell selection for enriching circulating tumor cells (CTCs) from peripheral blood. It also allows sensitive analysis of breast cancer-associated gene expression in enriched CTCs by reverse transcription and PCR. The high performance of AdnaTest BreastCancer has been demonstrated in dozens of peer-reviewed publications. Several studies have reported that HER2 expression is different in primary tumors compared to CTCs. In addition, AdnaTestBreast HER2 overexpression profile corresponds to HER2 metastatic phenotype; and HER2 detected by the AdnaTestBreast and AdnaTest EMT-2/StemCell seems to initiate EMT and tumor stemness.

Back to top